<DOC>
	<DOCNO>NCT02722447</DOCNO>
	<brief_summary>The treatment isolate distal deep vein thrombosis remain one debated issue field venous thromboembolism study directly address issue treatment objectively confirm isolated distal deep vein thrombosis . Aim study assess long-term risk recurrent venous thrombotic event patient first acute symptomatic isolated distal deep vein thrombosis leg treat standard ( 12 week ) shorter ( 6 week ) duration therapy rivaroxaban .</brief_summary>
	<brief_title>Rivaroxaban Treatment Symptomatic Isolated Distal Deep Vein Thrombosis</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Objective diagnosis isolate distal deep vein thrombosis within 72 hour evaluation inclusion study type parenteral treatment administer therapeutic dos 3 day less ( maximum accept dos low molecular weight heparin : 6 dos ; fondaparinux : 3 dos ) . Age &lt; 18 year Any absolute contraindication anticoagulant treatment Pregnancy breastfeed Presence active cancer Concomitant presence proximal deep vein thrombosis pulmonary embolism Any concomitant indication longterm anticoagulant treatment Creatinine clearance â‰¤30 ml/min , accord CockcroftGault equation Cirrhosis ChildPugh score B C Liver disease associate coagulopathy high risk bleed Any contraindication rivaroxaban per local SmPC Failure provide write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>